Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
P2.04 - Clinical Design, Statistics and Clinical Trials
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
-
+
P2.04-005 - GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC
09:30 - 09:30 | Presenter: Jürgen Wolf | Author(s): Ji-Youn Han, Makoto Nishio, P. Souquet, Luis Paz-Ares, F. De Marinis, Takashi Seto, M. De Jonge, T.M. Kim, Johan F. Vansteenkiste, Daniel SW Tan, Edward Brian Garon, H.J. Groen, Maximilian Johannes Hochmair, Enriqueta Felip, Noemi Reguart, M. Thomas, T.R. Overbeck, K. Ohashi, M. Giovannini, R. Yura, A. Joshi, M. Akimov, R. Heist
- Abstract
Loading...
-
+
GR 02 - Management of Immunotherapy-Related Adverse Events
- 11:00 - 12:30
- 10/17/2017
- Location: Main Hall
- Type: Grand Rounds
- Track: Immunology and Immunotherapy
- Moderators:Edward Brian Garon, Makoto Nishio
-
+
GR 02.03 - Pathophysiology of Immunotherapy-related Toxicity
11:12 - 11:27 | Presenter: Ji-Youn Han
- Abstract
Loading...
-
+
MA 10 - Immunotherapy I
- 11:00 - 12:30
- 10/17/2017
- Location: Room 303 + 304
- Type: Mini Oral
- Track: Immunology and Immunotherapy
- Moderators:S. Wang, Robert Pirker
-
+
MA 10.03 - 3-Year Survival and Duration of Response in Randomized Phase II Study of Atezolizumab vs Docetaxel in 2L/3L NSCLC (POPLAR)
11:10 - 11:15 | Presenter: Keunchil Park | Author(s): C. Lewanski, Shirish M Gadgeel, L. Fehrenbacher, Julien Mazieres, A. Rittmeyer, Ji-Youn Han, A. Artal-Cortes, F. Braiteh, M. Gandhi, W. Yu, C. Matheny, P. He, A. Sandler, M. Ballinger, Johan F. Vansteenkiste
- Abstract
Loading...
-
+
OA 09 - EGFR TKI Resistance
- 11:00 - 12:30
- 10/17/2017
- Location: Room 301 + 302
- Type: Oral
- Track: Advanced NSCLC
- Moderators:Thanyanan Reungwetwattana, Lecia V Sequist
-
+
OA 09.03 - TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
11:20 - 11:30 | Presenter: Myung-Ju Ahn | Author(s): Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. Tsai, James Chih-Hsin Yang, Helena Yu, L. Horn, K. Lee, V. Haddad, M.M. Frigault, G. Ahmed, L. Yang, D. Ghiorghiu, Geoffrey R. Oxnard
- Abstract
Loading...
-
+
OA 10 - Liquid Biopsy for Genomic Alterations
- 11:00 - 12:30
- 10/18/2017
- Location: F201 + F202 (Annex Hall)
- Type: Oral
- Track: Advanced NSCLC
- Moderators:Adrian G. Sacher, Pasi A Jänne
-
+
OA 10.01 - Detection of EGFR mutations from plasma ctDNA in the osimertinib Phase III trial (AURA3): comparison of three plasma assays
11:00 - 11:10 | Presenter: Myung-Ju Ahn | Author(s): Ji-Youn Han, C. Tsai, A. Delmonte, T. Hsia, J. Laskin, S. Kim, Y. He, T. Hida, M. Maemondo, T. Kato, S. Jenkins, A. Markovets, K.S. Thress, T. Mok
- Abstract
Loading...
-
+
OA 17 - Immunotherapy II
- 14:30 - 16:15
- 10/18/2017
- Location: Room 301 + 302
- Type: Oral
- Track: Immunology and Immunotherapy
- Moderators:Yuichiro Ohe, Anne Tsao
-
+
OA 17.07 - Long-Term Survival in Atezolizumab-Treated Patients with 2L+ NSCLC from Ph III Randomized OAK Study
15:35 - 15:45 | Presenter: Miyako Satouchi | Author(s): L. Fehrenbacher, Manuel Cobo Dols, Ji-Youn Han, J. Von Pawel, R. Bordoni, T. Hida, Keunchil Park, D. Moro-Sibilot, P. Conkling, C. Matheny, W. Yu, P. He, Marcin Kowanetz, M. Gandhi, M. Ballinger, A. Sandler, David R. Gandara
- Abstract
Loading...